KR920021575A - 뉴클레오시드의 디아스테레오머를 선택적으로 합성하는 방법 - Google Patents
뉴클레오시드의 디아스테레오머를 선택적으로 합성하는 방법 Download PDFInfo
- Publication number
- KR920021575A KR920021575A KR1019920008507A KR920008507A KR920021575A KR 920021575 A KR920021575 A KR 920021575A KR 1019920008507 A KR1019920008507 A KR 1019920008507A KR 920008507 A KR920008507 A KR 920008507A KR 920021575 A KR920021575 A KR 920021575A
- Authority
- KR
- South Korea
- Prior art keywords
- derivative
- choh
- chf
- alkyl
- pyrimidine base
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/06—Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Vehicle Step Arrangements And Article Storage (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (15)
- 하기 일반식(III)으로 표시되는 루이스산을 사용하여, 하기 일반식(II)로 표시되는 화합물의 단일 엔안티오머로 바람직한 퓨린 또는 피리미딘 염기 또는 그의 상도체 또는 유도체를 글리코실화 하는 단계를 포함하는 하기 일반식(I)로 표시되는 광학적으로 활성이 있는 시스-뉴클레오시드 및 뉴클레오시드 상동체 유도체를 디아스테레오머 선택적으로 제조하는 방법.상기식에서, R1은 수소 또는 아실; R2는 바람직한 퓨린 또는 피리미딘 염기 또는 그의 상동체 또는 유도체; W는 S, S=0, 또는 SO2, O, NZ, 또는 CH2; X는 0, S, S=0 또는 So2, O, NZ, CH2, CHF, CH, CHN3또는 CHOH; Y는 0, S. CH, CHF, 또는 CHOH; Z는 수소, 히드록실, 알킬 또는 아실; 이며 단 Y가 CH2이고 X가 0, S, S=0 또는 So2일때, W는 0, S, S=0 또는 So2가 아니며; R3는 치환된 카르보닐 또는 카르보닐 유도체; L은 이탈기; R5, R6및 R7은 각각 따로 수소; 플루오로, 브로모, 클로로, 요오드, C1-6알콕시 또는 C6-20아릴옥시로 임의 치환된 C1-20알킬; 할로겐, C1-20알킬 또는 C1-20알콕시로 임의 치환된 C7-20아르알킬; 플루오로, 브로모, 클로로, 요오드, C1-20알킬 또는 C1-20알콕시로 임의 치환된 C6-20아릴; 트리알킬실릴; 플루오로; 브로모; 클로로; 및 요오드로 구성된 군에서 선택된 것이고; R8은 플루오로; 브로모; 클로로; 요오드; 플루오로, 브로모, 클로로 또는 요오드로 임의 치환된 C1-20설포네이트 에스테르; 플루오로, 브로모, 클로로 또는 요오드로 임의 치환된 C1-20알킬 에스테르; 다가 할라이드; 일반식(R5)(R6)(R7) Si (여기에서 R5, R6, 및 R7은 상기 정의된 바와 같다)로 표시되는 삼중치환된 실릴기; 포화 또는 불포화된 셀레닐 C5-20아릴; 치환 또는 비치환된 C6-20아릴 설페닐; 치환 또는 비치환된 C6-20알콕시 알킬; 및 트리알킬 실록시기로 구성된 군중에서 선택된 것이다.
- 제1항에 있어서, 상기 글리코실화된 퓨린 또는 피리미딘 염기 또는 그의 상동체 또는 유도체의 R3를 환원시켜 일반식(I)로 표시되는 광학적으로 활성이 있는 시스-뉴클레오시스 또는 뉴클레오시드 상동체 또는 유도체를 제조하는 단계를 추가로 포함하는 방법.
- 제1항에 있어서, 상기 바람직한 퓨린 또는 피리미딘 염기물 글리코실화 하기전에 키랄 보조제를 사용하여 상기 일반식(II)의 화합물 단일 엔안티오머로 분할하는 단계를 추가로 포함하는 방법.
- 제1항 내지 제13항중 어느 한항에 있어서, R2가 피리미딘 염기인 방법.
- 제4항에 있어서, 상기 피리미딘염기는 시트신인 방법.
- 제4항에 있어서, 상기 피리미딘 염기는 5-플루오로시토신인 방법.
- 제1항 내지 제3항중 어느 한항에 있어서, 상기 루이스산은 트리메틸실린 트리플레이트와 요오드트리 메틸 실란으르 구성된 군에서 선택된 것인 방법.
- 제3항에 있어서, 상기 키랄 보조제는 (d)-멘톨 및 (1)-멘톨로 구성된 군에서 선택된 것인 방법.
- 제1항 내지 제3항중 어느 한항에 있어서, R3가 알콕시 카르보닐류, 카르복실류, 디에틸 카르복사미드, 피롤리딘 아미드, 메틸케톤 및 페닐케톤으로 구성된 군에서 선택된 것인 방법.
- 제9항에 있어서, R3가 알콕시카르보닐류 및 카르복실류로 구성된 군에서 선택된 것인 방법.
- 하기 일반식(II)로 표시되는 중간물질.상기식에서, W는 O, S=0, SO2, NZ 또는 CH2; X는 O, S=0, SO2, NZ, CH2CHF, CH, CHN3또는 CHOH; Y는 O, S, CH2, CH, CHF 또는 CHOH; Z는 수소, 히드록실, 알킬 또는 아실; 단 Y가 CH2이고 X가 O, S, S=0 또는 SO2일때, W는 O, S, S=0 또는 SO2가 아니며; R는 치환된 카르보닐 또는 카르보닐 유도체; L은 이탈기이다.
- 하기 일반식(VI)으로 표시되는 중간물질.상기식에서, W는 O, S=0, SO2, NZ 또는 CH2; X는 O, S=0, SO2, NZ, CH2CHF, CH 또는 CHN3또는 CHOH; Y는 O, S, CH2, CH, CHF 또는 CHOH; Z는 수소, 히드록실, 알킬 또는 아실; 단 Y가 CH2이고 X가 O, S, S=0 또는 SO2일때, W는 O, S, S=0 또는 SO2가 아니며; R3는 치환된 카르보닐 또는 카르보닐 유도체; R4는 키랄 보조제; L은 이탈기이다.
- 하기 일반식(VII)로 표시되는 중간물질.상기식에서, W는 O, S=0, SO2, NZ 또는 CH2; X는 O, S=0, SO2, NZ, CH2CHF, CH 또는 CHN3, 또는 CHOH; Y는 O, S, CH2, CH, CHF 또는 CHOH; Z는 수소, 히드록실, 알킬 또는 아실; 단 Y가 CH2이고 X가 O, S, S=0 또는 SO2일때, W는 O, S, S=0 또는 SO2가 아니며; R2는 퓨린 또는 피리미딘 염기 또는 그의 상동체 또는 유도체 이며; R3는 치환된 카르보닐 또는 카르보닐 유도체; R4는 키랄보조제이다.
- 하기 일반식(VIII)로 표시되는 중간물질.상기식에서, W는 O, S=0, SO2, NZ 또는 CH2; X는 O, S=0, SO2, NZ, CH2CHF, CH 또는 CHN3, 또는 CHOH; Y는 O, S, CH2, CH, CHF 또는 CHOH; Z는 수소, 히드록실, 알킬 또는 아실; 단 Y가 CH2이고 X가 O, S, S=0 또는 SO2일때, W는 O, S, S=0 또는 SO2가 아니며; R2는 퓨린 또는 피리미딘 염기 또는 그의 상동체 또는 유도체 이며; R3는 치환된 카르보닐 또는 카르보닐 유도체이다.
- 시스 및 트랜스-2R-카르보에톡시-5-히드록시테르라히드로푸란; 시스 및 트랜스-2S-카르보에톡시-5-히드록시테트라히드로푸란; 시스 및 트랜스-2R-카르보에톡시-5-아세톡시테트라히드로푸란; 시스 및 트랜스-2S-카르보에톡시-5-아세톡시테트라히드로푸란; 1'S-(N-4-아세틸 시토신-1-일)-4'R-카르보 에톡시테트라 히드로푸란; 1'S-(시토신-1-일)-4'R-카르보 에톡시테트라 히드로푸란; 1'R-(5-플루오로시토신-1-일)-4'S-카르보에톡시테트라 히드로푸란 및 1'S-(5-플루오로 시토신-1-일)-4'S-카르보에톡시테트라 히드로푸란; 및 1'S-(5-플루오로시토신-1-일)-4'R-카르보에톡시테트라 히드로푸란 및 1'R-(5-플루오로 시토신-1-일)-4'R-카르보에톡시테트라 히드로푸란으로 구성된 군에서 선택된 중간물질.※ 참고사항:최초출원 내용에 의하여 공개되는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70337991A | 1991-05-21 | 1991-05-21 | |
US07/703,379 | 1991-05-21 | ||
US7/703,379 | 1991-05-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR920021575A true KR920021575A (ko) | 1992-12-18 |
KR0160144B1 KR0160144B1 (ko) | 1998-11-16 |
Family
ID=24825144
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920008507A KR0160144B1 (ko) | 1991-05-21 | 1992-05-20 | 뉴클레오시드의 부분 입체 이성체를 선택적으로 합성하는 방법 |
KR1019920008694A KR100232012B1 (ko) | 1991-05-21 | 1992-05-20 | 뉴클레오시드의 부분입체이성질체를 선택적으로 합성하는 방법 |
KR1019990027976A KR100242921B1 (ko) | 1991-05-21 | 1999-07-12 | 뉴클레오시드의 부분입체이성질체를 선택적으로 합성하는 방법 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920008694A KR100232012B1 (ko) | 1991-05-21 | 1992-05-20 | 뉴클레오시드의 부분입체이성질체를 선택적으로 합성하는 방법 |
KR1019990027976A KR100242921B1 (ko) | 1991-05-21 | 1999-07-12 | 뉴클레오시드의 부분입체이성질체를 선택적으로 합성하는 방법 |
Country Status (34)
Country | Link |
---|---|
US (5) | US5756706A (ko) |
EP (2) | EP0515156B1 (ko) |
JP (3) | JP3229013B2 (ko) |
KR (3) | KR0160144B1 (ko) |
CN (6) | CN1038591C (ko) |
AT (2) | ATE157662T1 (ko) |
AU (4) | AU655973B2 (ko) |
BG (2) | BG61696B1 (ko) |
CA (2) | CA2069063C (ko) |
CZ (3) | CZ280857B6 (ko) |
DE (2) | DE69221936T2 (ko) |
DK (2) | DK0515156T3 (ko) |
EE (1) | EE03044B1 (ko) |
ES (2) | ES2104832T3 (ko) |
FI (3) | FI109025B (ko) |
GR (2) | GR3018941T3 (ko) |
GT (1) | GT199800047A (ko) |
HK (2) | HK132196A (ko) |
HU (2) | HU221850B1 (ko) |
IE (2) | IE921618A1 (ko) |
IL (6) | IL116109A (ko) |
MD (1) | MD1155C2 (ko) |
MX (2) | MX9202404A (ko) |
NO (2) | NO301010B1 (ko) |
NZ (2) | NZ242818A (ko) |
OA (1) | OA10212A (ko) |
PL (3) | PL176026B1 (ko) |
RO (1) | RO116812B1 (ko) |
RU (4) | RU2223960C2 (ko) |
SG (1) | SG43863A1 (ko) |
SK (2) | SK279438B6 (ko) |
TW (4) | TW366350B (ko) |
WO (2) | WO1992020696A1 (ko) |
ZA (2) | ZA923640B (ko) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903224B2 (en) | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
US6175008B1 (en) | 1988-04-11 | 2001-01-16 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
US6350753B1 (en) | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
HU226137B1 (en) * | 1989-02-08 | 2008-05-28 | Shire Canada Inc | Process for preparing substituted 1,3-oxathiolanes with antiviral properties |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5728575A (en) | 1990-02-01 | 1998-03-17 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US5587480A (en) * | 1990-11-13 | 1996-12-24 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US5925643A (en) * | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
US6812233B1 (en) | 1991-03-06 | 2004-11-02 | Emory University | Therapeutic nucleosides |
US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
ZA923640B (en) * | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
GB9226879D0 (en) * | 1992-12-23 | 1993-02-17 | Iaf Biochem Int | Anti-viral compounds |
US6444656B1 (en) | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
US6005107A (en) * | 1992-12-23 | 1999-12-21 | Biochem Pharma, Inc. | Antiviral compounds |
GB9226927D0 (en) * | 1992-12-24 | 1993-02-17 | Iaf Biochem Int | Dideoxy nucleoside analogues |
US5627160A (en) * | 1993-05-25 | 1997-05-06 | Yale University | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents |
TW374087B (en) * | 1993-05-25 | 1999-11-11 | Univ Yale | L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents |
GB9311709D0 (en) * | 1993-06-07 | 1993-07-21 | Iaf Biochem Int | Stereoselective synthesis of nucleoside analogues using bicycle intermediate |
US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
CA2171550C (en) | 1993-09-10 | 2008-08-26 | Raymond F. Schinazi | Nucleosides with anti-hepatitis b virus activity |
US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
IL113432A (en) * | 1994-04-23 | 2000-11-21 | Glaxo Group Ltd | Process for the diastereoselective synthesis of nucleoside analogues |
GB9413724D0 (en) * | 1994-07-07 | 1994-08-24 | Wellcome Found | Therapeutic nucleosides |
US6448235B1 (en) | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
US5869461A (en) * | 1995-03-16 | 1999-02-09 | Yale University | Reducing toxicity of L-nucleosides with D-nucleosides |
GB9506644D0 (en) * | 1995-03-31 | 1995-05-24 | Wellcome Found | Preparation of nucleoside analogues |
ES2276404T3 (es) | 1995-06-07 | 2007-06-16 | Emory University | Nucleosidos con actividad antivirus de la hepatitis-b. |
CN1201463A (zh) * | 1995-11-02 | 1998-12-09 | 株式会社钟根堂 | 新型核苷衍生物及其制备方法 |
GB9600143D0 (en) | 1996-01-05 | 1996-03-06 | Wellcome Found | Therapeutic compounds |
EP0799834A1 (en) * | 1996-04-04 | 1997-10-08 | Novartis AG | Modified nucleotides |
US6005097A (en) * | 1996-06-14 | 1999-12-21 | Vion Pharmaceuticals, Inc. | Processes for high-yield diastereoselective synthesis of dideoxynucleosides |
US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
US6022876A (en) | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
EP0970100B1 (en) | 1997-02-13 | 2003-11-12 | Glaxo Group Limited | Benzimidazole derivatives |
AU6898498A (en) | 1997-04-07 | 1998-10-30 | Triangle Pharmaceuticals, Inc. | Use of mkc-442 in combination with other antiviral agents |
ES2205527T3 (es) | 1997-06-10 | 2004-05-01 | Glaxo Group Limited | Derivados de bencimidazol. |
WO1999006424A1 (en) | 1997-07-30 | 1999-02-11 | The Regents Of The University Of Michigan | Lyxofuranosyl benzimidazoles as antiviral agents |
US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
ES2232169T3 (es) | 1998-08-12 | 2005-05-16 | Gilead Sciences, Inc. | Procedimiento de fabricacion de nucleosidos de 1,3-oxatiolano. |
US6979561B1 (en) | 1998-10-09 | 2005-12-27 | Gilead Sciences, Inc. | Non-homogeneous systems for the resolution of enantiomeric mixtures |
ATE254126T1 (de) | 1998-12-23 | 2003-11-15 | Shire Biochem Inc | Antivirale nukleosidanaloga |
US7115584B2 (en) | 1999-01-22 | 2006-10-03 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
US7635690B2 (en) | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
DE60011637T2 (de) | 1999-09-24 | 2004-11-11 | Shire Biochem Inc., Laval | Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen |
WO2001032153A2 (en) | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
US6436948B1 (en) | 2000-03-03 | 2002-08-20 | University Of Georgia Research Foundation Inc. | Method for the treatment of psoriasis and genital warts |
CA2308559C (en) * | 2000-05-16 | 2005-07-26 | Brantford Chemicals Inc. | 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues |
CA2788498C (en) * | 2001-03-01 | 2016-02-16 | Gilead Sciences, Inc. | Polymorphic and other crystalline forms of cis-ftc |
US6600044B2 (en) | 2001-06-18 | 2003-07-29 | Brantford Chemicals Inc. | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers |
SG176313A1 (en) * | 2001-10-01 | 2011-12-29 | Univ Virginia Patent Found | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
PL210841B1 (pl) | 2001-10-19 | 2012-03-30 | Isotechnika Inc | Sposób wytwarzania mieszaniny izomerów (E) i (Z) ISATX247 |
ITMI20012317A1 (it) * | 2001-11-06 | 2003-05-06 | Recordati Ind Chimica E Farma | Processo diastereoselettivo per la preparazione del'agente antivirale4-amino-1-(2r-idrossimetil-/1,3/ossatiolan-5s-i1)-1h-pirimidin-2-one |
AU2002364160A1 (en) * | 2001-12-14 | 2003-06-30 | Pharmasset Ltd. | Preparation of intermediates useful in the synthesis of antiviral nucleosides |
AU2003236757B2 (en) * | 2002-01-25 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Process for producing dioxolane nucleoside analogues |
US7365173B2 (en) * | 2002-02-04 | 2008-04-29 | American National Red Cross | Method for the production of pure virally inactivated butyrylcholinesterase |
CA2494183C (en) | 2002-08-06 | 2012-01-03 | Kyoichi A. Watanabe | Processes for preparing 1,3-dioxolane nucleosides |
DE602004014470D1 (de) | 2003-01-14 | 2008-07-31 | Gilead Sciences Inc | Zusammensetzungen und verfahren zur antiviralen kombinationstherapie |
ITMI20030578A1 (it) * | 2003-03-24 | 2004-09-25 | Clariant Lsm Italia Spa | Processo ed intermedi per la preparazione di emtricitabina |
US7785839B2 (en) | 2004-02-03 | 2010-08-31 | Emory University | Methods to manufacture 1,3-dioxolane nucleosides |
WO2006028618A1 (en) * | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
WO2006023272A1 (en) * | 2004-08-02 | 2006-03-02 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having a2a agonist activity |
CA2576826C (en) * | 2004-08-02 | 2014-09-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
US7837651B2 (en) * | 2004-08-31 | 2010-11-23 | Ethicon Endo-Surgery, Inc. | Infusion pump |
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
WO2007077505A2 (en) * | 2005-12-30 | 2007-07-12 | Ranbaxy Laboratories Limited | Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof |
WO2007120972A2 (en) * | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
WO2008053496A2 (en) * | 2006-10-30 | 2008-05-08 | Lupin Limited | An improved process for the manufacture of cis (-)-lamivudine |
KR20100072230A (ko) | 2007-09-26 | 2010-06-30 | 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 | 아자시티딘 유사체 및 이의 용도 |
AU2008331167A1 (en) * | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine |
WO2009069011A1 (en) * | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Process for the preparation of substituted 1,3-oxathiolanes |
US8350030B2 (en) | 2007-12-07 | 2013-01-08 | Matrix Laboratories Limited | Process for producing 5-fluoro-1-(2R, 5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine |
US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
PL2296633T3 (pl) | 2008-05-02 | 2016-03-31 | Gilead Sciences Inc | Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego |
US20110282046A1 (en) | 2009-01-19 | 2011-11-17 | Rama Shankar | Process for preparation of cis-nucleoside derivative |
MX2011008289A (es) | 2009-02-06 | 2011-09-15 | Gilead Sciences Inc | Tabletas para terapia combinada. |
CA2786227A1 (en) * | 2010-01-08 | 2011-07-14 | Hetero Research Foundation | Improved process for nucleosides |
DK3494972T3 (da) | 2010-01-27 | 2024-01-29 | Viiv Healthcare Co | Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion |
US20120295930A1 (en) * | 2010-02-03 | 2012-11-22 | Shankar Rama | Novel process for the preparation of cis-nucleoside derivative |
PL2542551T3 (pl) | 2010-03-04 | 2015-01-30 | Ranbaxy Laboratories Ltd | Sposób stereoselektywnego otrzymywania 5-fluoro-1-(2R,SS)-[2-(hydroksymetylo)-1,3-oksatiolan--5-ylo]cytozyny |
EP2377862A1 (en) | 2010-03-29 | 2011-10-19 | Esteve Química, S.A. | Process for obtaining emtricitabine |
WO2011141805A2 (en) | 2010-05-14 | 2011-11-17 | Lupin Limited | An improved process for the manufacture of lamivudine |
CN103221037A (zh) | 2010-11-12 | 2013-07-24 | 葛兰素惠尔康制造业私人有限公司 | 新药物组合物 |
WO2013021290A1 (en) | 2011-08-05 | 2013-02-14 | Lupin Limited | A stereoselective process for preparation of 1,3-oxathiolane nucleosides |
PT2750768T (pt) | 2011-08-30 | 2018-12-19 | Astex Pharmaceuticals Inc | Formulações de derivados de decitabina |
CN103242243B (zh) * | 2013-01-08 | 2015-08-19 | 北京大学 | 一种碱基乙酸甘油醚酯分子,其化学合成方法及其在基因治疗领域的应用 |
CN103288806A (zh) * | 2013-07-02 | 2013-09-11 | 山东大学 | 一种曲沙他滨的合成方法 |
BR112018000054A2 (pt) | 2015-07-02 | 2018-09-04 | Otsuka Pharmaceutical Co., Ltd. | composições farmacêuticas liofilizadas |
CN105037340B (zh) * | 2015-07-14 | 2018-08-10 | 福建广生堂药业股份有限公司 | 一种拉米夫定关键中间体手性异构体杂质的制备方法 |
WO2019025863A2 (en) | 2017-08-03 | 2019-02-07 | Otsuka Pharmaceutical Co., Ltd. | MEDICAMENT COMPOUND AND METHODS OF PURIFICATION |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1445013A (fr) * | 1964-07-09 | 1966-07-08 | Thomae Gmbh Dr K | Procédé pour fabriquer des nouveaux acides dioxolano-2-carboxyliques |
US4383114A (en) * | 1977-02-09 | 1983-05-10 | Regents Of The University Of Minnesota | Adenosine deaminase resistant antiviral purine arabinonucleosides |
US4231945A (en) * | 1978-11-08 | 1980-11-04 | Schering Corporation | S-5-(Azidomethyl or aminomethyl)-2-lower-alkoxytetrahydrofurans |
US4479942A (en) * | 1981-08-10 | 1984-10-30 | Fujisawa Pharmaceutical Co., Ltd. | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof |
US4855304A (en) * | 1985-01-10 | 1989-08-08 | Repligen Corporation | Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals |
DK363987A (da) * | 1986-08-08 | 1988-02-09 | Hoffmann La Roche | Pyrimidinderivater |
GB8621268D0 (en) * | 1986-09-03 | 1986-10-08 | Univ Strathclyde | Separation of substances |
US4997818A (en) * | 1987-09-21 | 1991-03-05 | The University Hospital | Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas |
SE8704298D0 (sv) * | 1987-11-03 | 1987-11-03 | Astra Ab | Compounds for use in therapy |
US4997926A (en) * | 1987-11-18 | 1991-03-05 | Scripps Clinic And Research Foundation | Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy |
JPH022349A (ja) * | 1988-02-17 | 1990-01-08 | Takeda Chem Ind Ltd | ピリミジンアナログ耐性化遺伝子dnaおよびその用途 |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
NZ228645A (en) * | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
DE3823127A1 (de) * | 1988-07-08 | 1990-01-11 | Rheinische Braunkohlenw Ag | Vorrichtung und verfahren zur reinigung von abwasser |
US4987224A (en) * | 1988-08-02 | 1991-01-22 | University Of Georgia Research Foundation, Inc. | Method of preparation of 2',3'-dideoxynucleosides |
DE3827134A1 (de) * | 1988-08-10 | 1990-03-15 | Bayer Ag | Substituierte triazolyl- bzw. imidazolyl-hydroxyalkyldioxolane, verfahren zu ihrer herstellung und ihre verwendung als mikrobizide, oxiranyldioxolane, dioxolanylketone, oxiranylketone und (alpha)-halogenketone als zwischenprodukte und verfahren zu deren herstellung |
US5075225A (en) * | 1989-04-06 | 1991-12-24 | The Texas A&M University System | Process for the enzymatic synthesis of nucleosides |
NZ233197A (en) * | 1989-04-13 | 1991-11-26 | Richard Thomas Walker | Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions |
NZ234534A (en) * | 1989-07-17 | 1994-12-22 | Univ Birmingham | Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor |
IE904378A1 (en) * | 1989-12-20 | 1991-07-03 | Abbott Lab | Analogs of oxetanyl purines and pyrimidines |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
GB9014090D0 (en) * | 1990-06-25 | 1990-08-15 | Zaadunie Bv | Improvements in or relating to organic compounds |
WO1992010496A1 (en) * | 1990-12-05 | 1992-06-25 | University Of Georgia Research Foundation, Inc. | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES |
IL100965A (en) * | 1991-02-22 | 1999-12-31 | Univ Emory | 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it |
WO1992018517A1 (en) * | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
GB9109506D0 (en) * | 1991-05-02 | 1991-06-26 | Wellcome Found | Therapeutic nucleosides |
ZA923640B (en) * | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
-
1992
- 1992-05-19 ZA ZA923640A patent/ZA923640B/xx unknown
- 1992-05-19 ZA ZA923641A patent/ZA923641B/xx unknown
- 1992-05-20 PL PL92309052A patent/PL176026B1/pl unknown
- 1992-05-20 DK DK92304551.2T patent/DK0515156T3/da active
- 1992-05-20 NO NO921988A patent/NO301010B1/no not_active IP Right Cessation
- 1992-05-20 IL IL11610992A patent/IL116109A/en not_active IP Right Cessation
- 1992-05-20 CZ CZ932493A patent/CZ280857B6/cs not_active IP Right Cessation
- 1992-05-20 SG SG1996003228A patent/SG43863A1/en unknown
- 1992-05-20 NZ NZ242818A patent/NZ242818A/en not_active IP Right Cessation
- 1992-05-20 RU RU99115480/04A patent/RU2223960C2/ru active
- 1992-05-20 SK SK1293-93A patent/SK279438B6/sk not_active IP Right Cessation
- 1992-05-20 DK DK92304552.0T patent/DK0515157T3/da active
- 1992-05-20 PL PL92301340A patent/PL170869B1/pl unknown
- 1992-05-20 DE DE69221936T patent/DE69221936T2/de not_active Expired - Lifetime
- 1992-05-20 AU AU16394/92A patent/AU655973B2/en not_active Expired
- 1992-05-20 KR KR1019920008507A patent/KR0160144B1/ko not_active IP Right Cessation
- 1992-05-20 EP EP92304551A patent/EP0515156B1/en not_active Expired - Lifetime
- 1992-05-20 WO PCT/CA1992/000209 patent/WO1992020696A1/en active IP Right Grant
- 1992-05-20 RO RO93-01554A patent/RO116812B1/ro unknown
- 1992-05-20 MD MD95-0172A patent/MD1155C2/ro unknown
- 1992-05-20 AU AU16908/92A patent/AU1690892A/en not_active Abandoned
- 1992-05-20 SK SK1294-93A patent/SK281954B6/sk not_active IP Right Cessation
- 1992-05-20 AU AU16395/92A patent/AU668086B2/en not_active Ceased
- 1992-05-20 IL IL101932A patent/IL101932A/xx not_active IP Right Cessation
- 1992-05-20 CA CA002069063A patent/CA2069063C/en not_active Expired - Lifetime
- 1992-05-20 AT AT92304552T patent/ATE157662T1/de active
- 1992-05-20 ES ES92304552T patent/ES2104832T3/es not_active Expired - Lifetime
- 1992-05-20 NO NO921989A patent/NO300593B1/no unknown
- 1992-05-20 KR KR1019920008694A patent/KR100232012B1/ko not_active IP Right Cessation
- 1992-05-20 RU RU93058554A patent/RU2105009C1/ru not_active IP Right Cessation
- 1992-05-20 CZ CZ962224A patent/CZ222496A3/cs not_active IP Right Cessation
- 1992-05-20 ES ES92304551T patent/ES2084937T3/es not_active Expired - Lifetime
- 1992-05-20 HU HU9303297A patent/HU221850B1/hu active IP Right Grant
- 1992-05-20 IL IL116176A patent/IL116176A/en not_active IP Right Cessation
- 1992-05-20 DE DE69208144T patent/DE69208144T2/de not_active Expired - Fee Related
- 1992-05-20 WO PCT/CA1992/000211 patent/WO1992020669A1/en active IP Right Grant
- 1992-05-20 NZ NZ242817A patent/NZ242817A/en not_active IP Right Cessation
- 1992-05-20 PL PL92301339A patent/PL168910B1/pl not_active IP Right Cessation
- 1992-05-20 RU RU93058362A patent/RU2140925C1/ru active
- 1992-05-20 HU HU9303296A patent/HU223838B1/hu not_active IP Right Cessation
- 1992-05-20 CZ CZ932492A patent/CZ285220B6/cs not_active IP Right Cessation
- 1992-05-20 AT AT92304551T patent/ATE133958T1/de not_active IP Right Cessation
- 1992-05-20 IL IL10193192A patent/IL101931A/en not_active IP Right Cessation
- 1992-05-20 US US08/142,389 patent/US5756706A/en not_active Expired - Fee Related
- 1992-05-20 EP EP92304552A patent/EP0515157B1/en not_active Expired - Lifetime
- 1992-05-20 CA CA002069024A patent/CA2069024C/en not_active Expired - Fee Related
- 1992-05-20 RU RU96119766/04A patent/RU2163909C2/ru not_active IP Right Cessation
- 1992-05-20 AU AU16913/92A patent/AU1691392A/en not_active Abandoned
- 1992-05-21 JP JP12915592A patent/JP3229013B2/ja not_active Expired - Lifetime
- 1992-05-21 MX MX9202404A patent/MX9202404A/es unknown
- 1992-05-21 MX MX9202395A patent/MX9202395A/es unknown
- 1992-05-21 CN CN92103921A patent/CN1038591C/zh not_active Expired - Lifetime
- 1992-05-21 JP JP12916392A patent/JP3330972B2/ja not_active Expired - Fee Related
- 1992-05-21 US US08/142,387 patent/US5696254A/en not_active Expired - Lifetime
- 1992-05-21 CN CN92103924A patent/CN1035555C/zh not_active Expired - Fee Related
- 1992-06-02 TW TW081104323A patent/TW366350B/zh not_active IP Right Cessation
- 1992-06-02 TW TW088109374A patent/TW467907B/zh not_active IP Right Cessation
- 1992-06-02 TW TW081104321A patent/TW366349B/zh not_active IP Right Cessation
- 1992-06-02 TW TW088109433A patent/TWI245046B/zh not_active IP Right Cessation
- 1992-07-01 IE IE161892A patent/IE921618A1/en not_active IP Right Cessation
- 1992-07-01 IE IE921619A patent/IE76741B1/en not_active IP Right Cessation
-
1993
- 1993-11-19 FI FI935150A patent/FI109025B/fi active
- 1993-11-19 FI FI935151A patent/FI106377B/fi not_active IP Right Cessation
- 1993-11-19 OA OA60440A patent/OA10212A/en unknown
- 1993-12-20 BG BG98311A patent/BG61696B1/bg unknown
- 1993-12-20 BG BG98310A patent/BG61695B1/bg unknown
-
1994
- 1994-10-20 EE EE9400283A patent/EE03044B1/xx unknown
-
1995
- 1995-03-10 CN CN95102412A patent/CN1050603C/zh not_active Expired - Lifetime
- 1995-06-05 US US08/460,856 patent/US5663320A/en not_active Expired - Lifetime
- 1995-06-05 US US08/464,960 patent/US5744596A/en not_active Expired - Fee Related
- 1995-06-05 US US08/464,317 patent/US5693787A/en not_active Expired - Lifetime
- 1995-11-23 IL IL11610995A patent/IL116109A0/xx unknown
- 1995-11-28 IL IL11617695A patent/IL116176A0/xx unknown
-
1996
- 1996-02-08 GR GR960400299T patent/GR3018941T3/el unknown
- 1996-07-18 HK HK132196A patent/HK132196A/xx not_active IP Right Cessation
-
1997
- 1997-09-04 GR GR970400204T patent/GR3024617T3/el unknown
-
1998
- 1998-02-24 HK HK98101405A patent/HK1002431A1/xx not_active IP Right Cessation
- 1998-03-04 GT GT199800047A patent/GT199800047A/es unknown
- 1998-12-03 CN CN98122385A patent/CN1083450C/zh not_active Expired - Lifetime
- 1998-12-03 CN CN98122384A patent/CN1097049C/zh not_active Expired - Lifetime
- 1998-12-03 CN CN98122383A patent/CN1109030C/zh not_active Expired - Lifetime
-
1999
- 1999-07-12 KR KR1019990027976A patent/KR100242921B1/ko not_active IP Right Cessation
-
2000
- 2000-08-29 FI FI20001900A patent/FI20001900A/fi unknown
-
2001
- 2001-05-07 JP JP2001136217A patent/JP3704055B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920021575A (ko) | 뉴클레오시드의 디아스테레오머를 선택적으로 합성하는 방법 | |
US6051709A (en) | Process for the diastereoselective synthesis of nucleoside analogues | |
ATE176236T1 (de) | Verfahren zur herstellung von diorganodialkoxysilanen | |
KR950701902A (ko) | 리그난계 화합물의 제조방법(process for producing lignan compound) | |
KR890000503A (ko) | 알콕시 실란의 제조방법 | |
SE9101482D0 (sv) | Foerfarande foer framstaellning av mellanprodukter anvaendbara foer syntes av bensotiazepiner | |
US4940813A (en) | Resolution of a carboxylic acid | |
KR910006288A (ko) | 신규 제조방법 | |
KR960000904A (ko) | 실라시클로헥산 화합물의 제조방법 | |
KR920012021A (ko) | (s)-비닐 및 -알레닐 gaba의 제조방법 | |
KR940005806A (ko) | 델타 발레로락톤의 라세미 혼합물을 분리하기 위한 효소적 방법 | |
DK11788D0 (da) | Stereobevarende syntese af 1-substituerede (s)- og (r)-2-aminometylpyrrolidiner og mellemprodukter dertil | |
KR910009647A (ko) | 3,4-에폭시부티레이트의 제조방법 및 이를 위한 중간체 | |
ATE312107T1 (de) | Verfahren zur herstellung von alkyllithium- verbindungen | |
ATE155132T1 (de) | Verfahren zur herstellung von amino- thiadiazolylacetylhaliden | |
ATE319722T1 (de) | Verfahren zur herstellung von vitamin-d analogen | |
KR950023641A (ko) | (2S,3aS,7aS)-2-(히드록시메틸)옥타히드로인돌, 그 제조방법 및 이를 이용한 광학활성을 갖는 (S)-이차 알코올의 합성법 | |
KR970010747A (ko) | 7-치환-3,5-디히드록시-6-헵텐산 화합물 및 그 제조방법 | |
DE69711112D1 (de) | Sulfonat von Glutathion-Monoester | |
KR970042541A (ko) | 알킬 페닐프로피오네트 유도체-14c의 제조방법 | |
KR920002618A (ko) | 아릴알킬메틸실란의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080808 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |